Project Grant R61CA291212
Award Date
8/8/24
Completion Date
7/31/27
Dollars Obligated
$414K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Argosmd, Inc. to develop a low-cost, non-invasive "Mini-Reflectance Confocal Microscope (Mini-RCM)" device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging microscopy tool that can improve upon existing Reflectance Confocal Microscopy (RCM) technology, which is currently limited in adoption due to...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $310,185 to New York University School of Medicine to conduct analytical and clinical validation of an advanced DNA methylation assay to predict recurrence in stage II melanoma patients. The project aims to refine and validate a 13-probe methylation signature that can accurately identify melanoma recurrence and mortality risk in stage II patients, using a large...
This $593,383 Project Grant, awarded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system for rapid and precise diagnosis of thyroid cancer and lymph node metastasis. The primary awardee, The Methodist Hospital Research Institute, is collaborating with The Johns Hopkins University on this project. The proposed system aims to eliminate...
Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to conduct research on melanoma bone metastasis. The goal is to better understand how melanoma cells infiltrate the bone microenvironment and interact with the immune system, in order to develop improved treatments for melanoma patients with bone metastases. The 2-year project will utilize preclinical murine models to examine the role...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $568,151 to the Regents of the University of Michigan. The grant will fund research to develop a real-time functional photoacoustic imaging platform with the capability to quantitatively evaluate prostate cancer tumor heterogeneity and microenvironment for improved prostate cancer diagnosis and prognosis. The research aims to optimize photoacoustic-nanoparticle contrast...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop their digital pathology "laboratory-in-a-box" solution that rapidly produces and analyzes high-resolution, 3D digital pathology images for skin cancer detection at the point of care. The specific goals are to: 1) refine the AI algorithms for improved detection of basal and squamous cell carcinomas, 2) develop...